CD8A and neoplasm: A study with the anti-PD1 antibody pembrolizumab using mass cytometry and flow cytometry of peripheral blood mononuclear cells showed that the reinvigoration of Ki67+ circulating exhausted-phenotype CD8+ T cells (Tex) in relation to pretreatment tumor burden correlated with clinical response [11].